ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS
    2.
    发明申请
    ACTIVE AGENT PRODRUGS WITH HETEROCYCLIC LINKERS 审中-公开
    主动代理产品与异质连接器

    公开(公告)号:WO2012122422A3

    公开(公告)日:2014-04-24

    申请号:PCT/US2012028367

    申请日:2012-03-08

    IPC分类号: C07D221/28 A61K47/00

    摘要: The embodiments provide prodrug compounds of Formulae I-XVII. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug compound of Formulae I-XVII that provides controlled release of an active agent. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of an active agent from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

    摘要翻译: 实施方案提供式I-XVII的前药化合物。 本公开还提供组合物及其使用方法,其中组合物包含提供活性剂受控释放的式I-XVII的前药化合物。 这样的组合物可以任选地提供胰蛋白酶抑制剂,其与介导活性剂从前药的受控释放的酶相互作用,以减弱前药的酶切。

    SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF
    6.
    发明申请
    SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF 审中-公开
    选择性的CYSTEINE PROTEASE抑制剂及其用途

    公开(公告)号:WO2012140500A9

    公开(公告)日:2013-10-24

    申请号:PCT/IB2012000747

    申请日:2012-04-15

    摘要: The present invention relates to compounds of Formula I, II, IA-VA, IVA1-1VA5, 11IA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1 -IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease).

    摘要翻译: 本发明涉及式I,II,IA-VA,IVA1-1VA5,11A1-IIIA5的化合物及其药物用途。 本发明的特定方面涉及这些化合物用于选择性抑制一种或多种半胱氨酸蛋白酶的用途。 还描述了将式I,II,IA-VA,IVA1-IVA5,IIIA1-IIIA5的化合物用于预防和/或治疗受试者中的各种疾病和病症的方法,包括半胱氨酸蛋白酶介导的疾病和/或 胱天蛋白酶介导的疾病如败血症,心肌梗死,癌症,组织萎缩,缺血,缺血性中风,脊髓损伤(SCI),创伤性脑损伤(TBI)和神经变性疾病如多发性硬化(MS),ALS,阿尔茨海默病, 帕金森病和亨廷顿疾病)。

    DIPEPTIDE LINKED MEDICINAL AGENTS
    9.
    发明申请
    DIPEPTIDE LINKED MEDICINAL AGENTS 审中-公开
    替代物连接药物

    公开(公告)号:WO2011162968A1

    公开(公告)日:2011-12-29

    申请号:PCT/US2011/039755

    申请日:2011-06-09

    IPC分类号: A61K38/28 C07K14/62

    摘要: A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration.

    摘要翻译: 提供了可以通过酰胺键与已知药物连接的非酶促自切割二肽元件。 通过化学不稳定驱动的反应,二肽将在生理条件下自发地从医药上裂解。 因此,二肽元件提供了将各种化合物与已知药物连接的方法,其中化合物随后在暴露于生理条件的预定时间后从药物释放。 例如,二肽可以连接到药物的活性位点以形成前体药物和/或二肽可以包含贮库聚合物,以在给药点隔离包含该复合物的可注射组合物。